RCS - IQ-AI Limited - Studies Show GaM Inhibits Pediatric Tumor Growth

IQ-AIAnnouncement

27/06/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230627:nRSa9433Da&default-theme=true

RNS Number : 9433D  IQ-AI Limited  27 June 2023

IQ-AI Ltd

("IQ-AI" or the "Company")

 

New Studies Show Oral Gallium Maltolate (GaM) Inhibits Pediatric Tumor Growth

 

Imaging Biometrics, LLC (IB), a wholly-owned subsidiary of IQ-AI Ltd (LSE:
IQAI, OTCQB: IQAIF), is pleased to share the results of two pre-clinical
studies that were presented at last week's 2023 Society of Neuro Oncology
(SNO) Pediatric Conference in Washington, DC. Each study, led by Dr. Mona
Al-Gizawiy, PhD from the Schmainda Lab at the Medical College of Wisconsin
(MCW), demonstrated inhibitory effects of oral GaM in two types of pediatric
brain tumors in vivo; atypical teratoid rhabdoid tumor (ATRT) and glioblastoma
multiforme (GBM). Oral GaM is the same agent being investigated in adult GBM
in IQ-AI's sponsored phase I clinical trial being conducted at MCW.

In 2022, it was estimated that approximately 5,500 new cases of brain tumors
were diagnosed in children age 0-19 in the US. While rare, brain and other
central nervous system (CNS) tumors still represent the largest cause of
cancer-related death in that age group. Both ATRT and GBM are highly
aggressive tumors that are associated with poor outcomes in children. The dire
prognosis is due in part to the poor response to limited treatment options
available.

The results of each study were consistent with previous in vitro work
conducted in the Schmainda Lab showing tumor growth inhibition and a survival
benefit from treatment with oral GaM. Median overall survival for ATRT was 89
days in the control group and 170 days in the treated group. For GBM, those
numbers were 21 and 49 days, respectively. Both studies concluded that
monotherapy with oral GaM profoundly inhibited growth and provided a
significant survival benefit.

In April, IB applied for Orphan Drug Designation to the US Food and Drug
Administration (FDA) for the use of GaM in pediatric brain tumors. The
application is under review and, if granted, would support the development and
evaluation of a new treatment alternative for an unmet clinical need.

--ENDS-

 

The Directors of the Company accept responsibility for the contents of this
announcement.

 

For further information, please contact:

 

 IQ-AI Ltd

 Trevor Brown/Vinod Kaushal/Brett Skelly/Michael Schmainda

 Tel: 020 7469 0930
 Peterhouse Capital Limited (Financial Adviser and Broker)

 Lucy Williams/Heena Karani

 Tel: 020 7220 9797

About Imaging Biometrics® LLC:  IB is a wholly-owned subsidiary of IQ-AI
Limited, (LON: IQAI) (OTCQB: IQAIF), and focuses on delivering quantitative
imaging platforms and therapeutics that transform how clinicians diagnose and
treat patients more efficiently and effectively. For more information about
Imaging Biometrics, visit the company's website at www.imagingbiometrics.com
(http://www.imagingbiometrics.com/) . Follow IB on Twitter, @IQAI_IB.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUNAVROSUNUAR